Combined effects of intraperitoneal administration of recombinant interleukin-2 and streptococcal preparation OK-432 in murine tumors

This publication has 23 references indexed in Scilit:

• A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone
  New England Journal of Medicine, 1987
• Pronounced antitumor effect of LAK-like cells induced in the peritoneal cavity of mice after intraperitoneal injection of OK-432, a killed Streptococcal preparation
  Cancer Immunology, Immunotherapy, 1986
• Biological Activity of Recombinant Human Interleukin-2 Produced in Escherichia coli
  Science, 1984
• Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome.
  Journal of Clinical Investigation, 1983
• Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
  The Journal of Experimental Medicine, 1982
• The Biochemistry, Biology, and Role of Interleukin 2 in the Induction of Cytotoxic T Cell and Antibody‐Forming B Cell Responses
  Immunological Reviews, 1982
• Interleukin-2 augments natural killer cell activity
  Nature, 1981
• In vitro augmentation of natural killing activity by OK-432
  International Journal of Immunopharmacology, 1981
• Cytolytic and proliferative activity of a permanent T killer cell line
  Nature, 1979
• Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows
  Science, 1976